Scholarlink

Abstract <p>A series of novel <i>N</i>-(3-cyano-4,5,6,7-tetrahydrobenzo[<i>b</i>]thiophen-2-yl)-2-(4-phenyl-5-(arylphenyl)-4<i>H</i>-1,2,4-triazol-3-ylthio)acetamide derivatives were synthesized, characterized, and evaluated for their cytotoxic potential. The synthesis, monitored by thin-layer chromatography (TLC), involved multiple steps, and the compounds were purified by recrystallization. The structures were confirmed using spectroscopic techniques, including NMR, Mass, and IR spectroscopy. The compounds were tested against MCF-7 (human breast cancer), HOP-62, and A-549 (human lung cancer) cell lines. Compound <b>6b</b> emerged as the most potent compound, displaying low LC50, TGI, and GI50 values across all cell lines. Other derivatives, such as <b>6a</b> and <b>6c</b>, showed moderate activity, while some exhibited negligible effects. These findings indicate that <b>6b</b> holds strong potential as an anticancer agent, while further optimization may enhance the efficacy of other derivatives.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis, Spectroscopic Characterization, and Cytotoxic Evaluation of Novel N-(3-Cyano-4,5,6,7Tetrahydrobenzo[b]thiophen-2-yl)-2-(4-phenyl-5-(arylphenyl)-4H-1,2,4-triazol-3-ylthio)acetamide Derivatives as Potential Anticancer Agents

  • 期刊论文

  • 发表日期：

    2025年2月1日

查看全文
  • Maharshi B. Shukla,
  • Jyotindra B. Mahyavanshi,
  • Kokila A. Parmar

摘要

Abstract

A series of novel N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-(4-phenyl-5-(arylphenyl)-4H-1,2,4-triazol-3-ylthio)acetamide derivatives were synthesized, characterized, and evaluated for their cytotoxic potential. The synthesis, monitored by thin-layer chromatography (TLC), involved multiple steps, and the compounds were purified by recrystallization. The structures were confirmed using spectroscopic techniques, including NMR, Mass, and IR spectroscopy. The compounds were tested against MCF-7 (human breast cancer), HOP-62, and A-549 (human lung cancer) cell lines. Compound 6b emerged as the most potent compound, displaying low LC50, TGI, and GI50 values across all cell lines. Other derivatives, such as 6a and 6c, showed moderate activity, while some exhibited negligible effects. These findings indicate that 6b holds strong potential as an anticancer agent, while further optimization may enhance the efficacy of other derivatives.